Who owns NEOLEUKIN THERAPEUTICS INC?
- CUSIP Number: 64049k203
Tip: Access positions for across all investors
Analyze quarterly positions in Neoleukin Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Neoleukin Therapeutics stock
Who bought or sold NEOLEUKIN THERAPEUTICS INC this quarter?
There are no current stakeholders of Neoleukin Therapeutics.
This is normal when the security:
- Has been acquired or taken private
- Has merged with another entity
- Has changed its name and has a new CUSIP (and/or symbol)
- Has been delisted and the ticker has changed
Please use Search to find the security you were looking for.
Who sold out of Neoleukin Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Baker Bros. Advisors | Sep 2023 | 1.2M | $4.8M |
| Redmile Group | Sep 2023 | 582k | $2.3M |
| Nantahala Capital Management | Sep 2023 | 300k | $1.2M |
| Bank of America Corporation | Sep 2023 | 232k | $916k |
| Vanguard Group | Sep 2023 | 202k | $796k |
| Millennium Management | Sep 2023 | 38k | $149k |
| Two Sigma Investments | Sep 2023 | 34k | $135k |
| Two Sigma Advisers | Sep 2023 | 34k | $134k |
| Point72 Asset Management | Sep 2023 | 27k | $108k |
| Citadel Advisors | Sep 2023 | 26k | $101k |
| Kynam Capital Management | Sep 2023 | 24k | $95k |
| Us Bancorp | Sep 2023 | 14k | $55k |
| Wells Fargo & Company | Sep 2023 | 1.7k | $6.5k |
| UBS Group | Sep 2023 | 231.00 | $903.002100 |
| Farther Finance Advisors | Sep 2023 | 200.00 | $790.000000 |